Company news

Share this article:
Schering-Plough ended its partnership with Novacea after its prostate cancer compound Asentar failed in clinical trials. The companies ended a late-stage study of the drug late last year citing an "imbalance" of deaths. Patients taking Asentar died more often than those taking a standard treatment. Asentar rights will be returned to Novacea. Despite the higher-than-expected number of deaths, the company said in published reports it still believes Asentar is a safe drug and called Schering-Plough's decision unexpected.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.